Maialen Zabalza Zudaire

Ms. Maialen Zabalza Zudaire

NNBi 2020 SL, Pamplona, Navarre, Spain

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2022 in Remote Sensing
Verified
Journal Article
Open access
PDF file
MZMaialen Zabalza Zudaire
Maialen Zabalza Zudaire
ABangela bernardini
angela bernardini
Many visual applications require high-resolution images for an adequate interpretation of the data stored within them. In remote sensing, the appearance of satellites such as Sentinel or Landsat has facilitated the access to data thanks to their free offer of multispectral images. However, the spatial resolution of these satellites is insufficient for many tasks. Therefore, the objective of this work is to apply deep learning techniques to increase the resolution of the Sentinel-2 Read-Green-Blue-NIR (RGBN) bands from the original 10 m to 2.5 m. This means multiplying the number of pixels in the resulting image by 4, improving the perception and visual quality. In this work, we implement a state-of-the-art residual learning-based model called Super-Resolution Residual Network (SRResNet), which we train using PlanetScope-Sentinel pairs of images. Our model, named SARNet (Spectral Attention Residual Network), incorporates Residual Channel Attention Blocks (RCAB) to improve the performance of the network and the visual quality of the results. The experiments we have carried out show that SARNet offers better results than other state-of-the-art methods.

12 August 2024 in Cancers
Verified
Journal Article
Open access
PDF file
OSOskitz Ruiz Sarrias
Oskitz Ruiz Sarrias
MPMaría Purificación Martínez del Prado
María Purificación Martínez del Prado
MSMaria Angeles Sala
Maria Angeles Sala
JSJosune Azcuna Sagarduy
Josune Azcuna Sagarduy
PCPablo Casado Cuesta
Pablo Casado Cuesta
OBOnintza Sayar Beristain
Onintza Sayar Beristain
Introduction: Large Language Models (LLMs), such as the GPT model family from OpenAI, have demonstrated transformative potential across various fields, especially in medicine. These models can understand and generate contextual text, adapting to new tasks without specific training. This versatility can revolutionize clinical practices by enhancing documentation, patient interaction, and decision-making processes. In oncology, LLMs offer the potential to significantly improve patient care through the continuous monitoring of chemotherapy-induced toxicities, which is a task that is often unmanageable for human resources alone. However, existing research has not sufficiently explored the accuracy of LLMs in identifying and assessing subjective toxicities based on patient descriptions. This study aims to fill this gap by evaluating the ability of LLMs to accurately classify these toxicities, facilitating personalized and continuous patient care. Methods: This comparative pilot study assessed the ability of an LLM to classify subjective toxicities from chemotherapy. Thirteen oncologists evaluated 30 fictitious cases created using expert knowledge and OpenAI’s GPT-4. These evaluations, based on the CTCAE v.5 criteria, were compared to those of a contextualized LLM model. Metrics such as mode and mean of responses were used to gauge consensus. The accuracy of the LLM was analyzed in both general and specific toxicity categories, considering types of errors and false alarms. The study’s results are intended to justify further research involving real patients. Results: The study revealed significant variability in oncologists’ evaluations due to the lack of interaction with fictitious patients. The LLM model achieved an accuracy of 85.7% in general categories and 64.6% in specific categories using mean evaluations with mild errors at 96.4% and severe errors at 3.6%. False alarms occurred in 3% of cases. When comparing the LLM’s performance to that of expert oncologists, individual accuracy ranged from 66.7% to 89.2% for general categories and 57.0% to 76.0% for specific categories. The 95% confidence intervals for the median accuracy of oncologists were 81.9% to 86.9% for general categories and 67.6% to 75.6% for specific categories. These benchmarks highlight the LLM’s potential to achieve expert-level performance in classifying chemotherapy-induced toxicities. Discussion: The findings demonstrate that LLMs can classify subjective toxicities from chemotherapy with accuracy comparable to expert oncologists. The LLM achieved 85.7% accuracy in general categories and 64.6% in specific categories. While the model’s general category performance falls within expert ranges, specific category accuracy requires improvement. The study’s limitations include the use of fictitious cases, lack of patient interaction, and reliance on audio transcriptions. Nevertheless, LLMs show significant potential for enhancing patient monitoring and reducing oncologists’ workload. Future research should focus on the specific training of LLMs for medical tasks, conducting studies with real patients, implementing interactive evaluations, expanding sample sizes, and ensuring robustness and generalization in diverse clinical settings. Conclusions: This study concludes that LLMs can classify subjective toxicities from chemotherapy with accuracy comparable to expert oncologists. The LLM’s performance in general toxicity categories is within the expert range, but there is room for improvement in specific categories. LLMs have the potential to enhance patient monitoring, enable early interventions, and reduce severe complications, improving care quality and efficiency. Future research should involve specific training of LLMs, validation with real patients, and the incorporation of interactive capabilities for real-time patient interactions. Ethical considerations, including data accuracy, transparency, and privacy, are crucial for the safe integration of LLMs into clinical practice.

30 April 2025 in Cancers
Verified
Journal Article
Open access
PDF file
MOMiguel Ortego
Miguel Ortego
OIOlast Arrizibita Iriarte
Olast Arrizibita Iriarte
AMAdriana Martinez-Lage
Adriana Martinez-Lage
AAAngel Vizcay Atienza
Angel Vizcay Atienza
LGLaura Álvarez Gigli
Laura Álvarez Gigli
Javier Rodríguez RodríguezJavier Rodríguez Rodríguez
Javier Rodríguez Rodríguez
Background: The purpose of this study was to evaluate the long-term outcomes of patients with locally advanced gastric adenocarcinoma (LAGC) intended to receive induction chemotherapy, chemoradiation and surgery and to develop an algorithm to estimate the individual risk of relapse in a population-based setting. Methods: Patients with LAGC (cT3-4 and/or N+) were retrospectively evaluated. A pathological response was graded according to the Becker criteria. The nodal regression grade was assessed by a 4-point scale (A–D). A comprehensive analysis of 155 individual patient variables was performed, and logistic regression (LR) was utilized to develop a predictive model for relapse risk. Results: From 2010 to 2024, 48 patients were analyzed. After a median follow-up of 49 months (range, 12–212), the 5-year actuarial PFS and OS rates were 44% and 48%, respectively. Four variables were identified as the most relevant features for training the LR model. Scores for the model accuracy, sensitivity and specificity (mean +/− sd) were 0.79 +/− 0.12, 0.74 +/− 0.221 and 0.88 +/− 0.14, respectively. For a validation dataset, the figures were 0.78, 0.88 and 0.73, respectively. Conclusions: This neoadjuvant strategy seems to correlate with a favorable long-term outcome in a subset of intestinal-type LAGA patients who achieve ypN0 features.